NEUROPATHIX, INC. (KLFE) [Rocket]

Overview

NEUROPATHIX, INC. (KLFE)

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
08/12/2022	NT 10-Q	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
06/13/2022	4	Form 4 - Statement of changes in beneficial ownership of securities:
06/02/2022	4	Form 4 - Statement of changes in beneficial ownership of securities:
05/23/2022	10-Q	Quarterly Report for the period ended March 31, 2022
05/16/2022	NT 10-Q	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
01/07/2022	4	PETKANAS DEAN (CEO) has filed a Form 4 on NEUROPATHIX, INC.
11/12/2021	10-Q	Quarterly Report for the period ended September 30, 2021

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	0.0	0.1	0.2	0.0	0.0	0.1	0.0
Revenue growth	-100.0%	-27.5%		-100.0%	-75.9%	2800.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.1	0.0
Gross profit	0.0	0.1	0.2	0.0	0.0	0.1	0.0
Gross margin		100.0%	100.0%		39.9%	64.8%	100.0%
Selling, general and administrative	4.5	2.5	1.2
Sales and marketing					0.0	0.1
Research and development				0.0
General and administrative				1.2	0.0	0.0	0.0
EBITA	-4.6	-4.6	4.5	-1.2	0.0	0.0	0.0
EBITA margin		-3628.3%	2615.4%		-91.6%	3.3%	-162.3%
Amortization of intangibles				0.0
EBIT	-4.6	-4.6	4.5	-1.2	0.0	0.0	0.0
EBIT margin		-3628.3%	2615.4%		-91.6%	3.3%	-162.3%
Pre-tax income	-4.5	-3.5	1.7	-1.3	0.0	0.0	0.0
Income taxes	0.0	0.0	0.8	0.4	0.0	0.0	0.0
Tax rate	0.0%	0.0%	46.6%		0.0%	0.0%	0.0%
Net income	0.0	0.0	0.0	-1.6	0.0	0.0	0.0
Net margin		0.0%	0.0%		-91.6%	3.3%	-162.3%

Diluted EPS	$0.00	$0.00	$0.00	($0.03)	$0.00	$0.00	$0.00
Shares outstanding (diluted)	74.6	71.2	68.8	48.5	9.5	9.5	9.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.